Cancer Letters
Volume 227, Issue 1 , Pages 75-81 , 8 September 2005

Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma

Received 20 October 2004 ,Revised 26 November 2004 ,Accepted 28 November 2004.

References 

  1. Wiestler OD, Schiffer D, Coons SW, Prayson RA, Rosenblum MK. Ependymoma,. In:  Kleihues P,  Cavenee WK editor. Tumours of the Nervous System. Lyon: IARC Press; 2000;p. 78–81
  2. Figarella-Branger D, Civatte M, Bouvier-Labit C, Gouvernet J, Gambarelli D, Gentet JC, et al. Prognostic factors in intracranial ependymomas in children. J. Neurosurg. 2000;93:605–613
  3. Reardon DA, Entrekin RE, Sublett J, Ragsdale S, Li H, Boyett J, et al. Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. Genes Chromosomes Cancer. 1999;24:230–237
  4. Ward S, Harding B, Wilkins P, Harkness W, Hayward R, Darling JL, et al. Gain of 1q and loss of 22 are the most common changes detected by comparative genomic hybridisation in paediatric ependymoma. Genes Chromosomes Cancer. 2001;32:59–66
  5. Carter M, Nicholson J, Ross F, Crolla J, Allibone R, Balaji V, et al. Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br. J. Cancer. 2002;86:929–939
  6. Slavc I, MacCollin MM, Dunn M, Jones S, Sutton L, Gusella JF, et al. Exon scanning for mutations of the NF2 gene in pediatric ependymomas, rhabdoid tumors and meningiomas. Int. J. Cancer. 1995;64:243–247
  7. Ebert C, von Haken M, Meyer-Puttlitz B, Wiestler OD, Reifenberger G, Pietsch T, et al. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am. J. Pathol. 1999;155:627–632
  8. Alonso ME, Bello MJ, Arjona D, Gonzalez-Gomez P, Lomas J, de Campos JM, et al. Analysis of the NF2 gene in oligodendrogliomas and ependymomas. Cancer Genet. Cytogenet. 2002;134:1–5
  9. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancers. Nat. Rev. Genet. 2002;3:415–428
  10. Bortolotto S, Chiado-Piat L, Cavalla P, Bosone I, Mauro A, Schiffer D. CDKN2A/p16 in ependymomas. J. Neurooncol. 2001;54:9–13
  11. Gonzalez-Gomez P, Bello MJ, Alonso ME, Arjona D, Lomas J, de Campos JM, et al. CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. Br. J. Cancer. 2003;88:109–114
  12. Rousseau E, Ruchoux MM, Scaravilli F, Chapon F, Vinchon M, De Smet C, et al. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathol. Appl. Neurobiol. 2003;29:574–583
  13. Alonso ME, Bello MJ, Gonzalez-Gomez P, Arjona D, de Campos JM, Gutierrez M, et al. Aberrant CpG island methylation of multiple genes in ependymal tumors. J. Neurooncol. 2004;67:159–165
  14. Waha A, Koch A, Hartmann W, Mack H, Schramm J, Sorensen N, et al. Analysis of HIC-1 methylation and transcription in human ependymomas. Int. J. Cancer. 2004;110:542–549
  15. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet. 2000;25:315–319
  16. Lusher ME, Lindsey JC, Latif F, Pearson AD, Ellison DW, Clifford SC. Bi-allelic epigenetic inactivation of the RASSF1A gene in medulloblastoma development. Cancer Res. 2002;62:5906–5911
  17. Horiguchi K, Tomizawa Y, Tosaka M, Ishiuchi S, Kurihara H, Mori M, et al. Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors. Oncogene. 2003;22:7862–7865
  18. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000;343:1350–1354
  19. Dong S, Pang JC, Hu J, Zhou LF, Ng HK. Transcriptional inactivation of TP73 expression in oligodendroglial tumours. Int. J. Cancer. 2002;98:370–375
  20. Yin D, Xie D, Hofmann WK, Miller CW, Black KL, Koeffler HP. Methylation, expression, and mutation analysis of the cell cycle control genes in human brain tumors. Oncogene. 2002;21:8372–8378
  21. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, et al. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers. Cancer Res. 1999;59:798–802
  22. Harada K, Toyooka S, Shivapurkar N, Maitra A, Reddy JL, Matta H, et al. Deregulation of caspase 8 and 10 expression in paediatric tumours and cell lines. Cancer Res. 2002;62:5897–5901
  23. Zuzak TJ, Steinhoff DF, Sutton LN, Phillips PC, Eggert A, Grotzer MA. Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma. Eur. J. Cancer. 2002;38:83–91
  24. Lindsey JC, Lusher ME, Anderton JA, Bailey S, Gilbertson RJ, Pearson AD, et al. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis. 2004;25:661–668
  25. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA. 1996;93:9821–9826
  26. Xing EP, Nie Y, Song Y, Yang GY, Cai YC, Wang LD, et al. Mechanisms of inactivation of p14ARF, p15INK4B, and p16INK4A genes in human esophageal squamous cell carcinoma. Clin. Cancer Res. 1999;5:2704–2713
  27. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res. 2000;60:1211–1216
  28. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 2000;6:529–535
  29. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997;25:2532–2534
  30. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene. 2001;20:1509–1518
  31. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA. 1999;96:8681–8686
  32. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J. Natl Cancer Inst. 2001;93:691–699
  33. Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res. 2001;61:7034–7038
  34. Fenton SL, Dallol A, Agathanggelou A, Hesson L, Ahmed-Choudhury J, Baksh S, et al. Identification of the E1A-regulated transcription factor p120 E4F as an interacting partner of the RASSF1A candidate tumor suppressor gene. Cancer Res. 2003;64:102–107
  35. Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol. Cell Biol. 2002;22:4309–4318
  36. Liu L, Tommasi S, Lee DH, Dammann R, Pfeifer GP. Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene. 2003;22:8125–8136
  37. Song MS, Song SJ, Ayad NG, Chang JS, Lee JH, Hong HK, et al. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat. Cell Biol. 2004;6:129–137

PII: S0304-3835(04)00940-1

doi: 10.1016/j.canlet.2004.11.044

Cancer Letters
Volume 227, Issue 1 , Pages 75-81 , 8 September 2005

Article Tools

* Image Usage & Resolution